Volitionrx (VNRX) Convertible Debt (2025)

Volitionrx (VNRX) reported Convertible Debt of $1.4 million for Q4 2025, down 36.32% quarter-over-quarter from $2.3 million in Q3 2025.

Volitionrx (VNRX) Convertible Debt (2025) Analysis & Trends

Volitionrx has reported Convertible Debt for 1 years, with the latest figure at $1.4 million in Q4 2025.

For the quarter ending Q4 2025, Convertible Debt changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $1.4 million, changed N/A from the prior year.
Convertible Debt for Q4 2025 stood at $1.4 million, down from $2.3 million in the prior quarter.
The five-year high for Convertible Debt was $2.9 million in Q2 2025, with the low at $1.4 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Volitionrx	53.00 Mn	50.54 Mn	-1.01 Mn

Download Data